Case Study

Scaling Up Strategy For Oncolytic Herpes Simplex Virus Type-1 Vector Manufacturing

Source: OBiO Tech

By Lingjing Tang, Jun Wang, Shiyi Mei, Zhengrui Xiong, Zihao Fang, Han Gao, Houliang Wei, and Weiran Shen, OBiO Tech

Bioreactor-GettyImages-801080522

Gene therapy offers immense promise for treating a multitude of diseases, but manufacturing the viral vectors needed for treatment remains a hurdle. This study addresses this bottleneck by introducing a novel, large-scale production method for herpes simplex virus type-1 (HSV-1) vectors, a potent weapon in the fight against cancer.

Traditionally, HSV-1 vector production relies on labor-intensive methods that limit production capacity. This research presents a game-changing approach using fixed-bed bioreactors, demonstrating successful large-scale production while maintaining high virus yield and quality. This innovative strategy significantly reduces manpower, materials, and space requirements, paving the way for cost-effective and efficient manufacturing of HSV-1 vectors. Discover how this advancement has the potential to accelerate the progress of gene therapy and bring it closer to widespread application.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online